NSEBagging/Receiving of orders/contracts1 Jul 2026 · 1 Jul 2026, 04:41 pm

Bagging/Receiving of orders/contracts

Sai Parenterals Limited · SAIPARENT

✦ AI Summary▲ PositiveOrder Win

Sai Parenterals Limited has informed the Exchange about bagging/receiving of orders/contracts. The company's subsidiary Noumed Pharmaceuticals Pty Limited has entered an OTC medicines supply agreement with Australia's leading pharmacy network valued at AUD 202 Millions (equivalent to INR 1300 crores). The agreement is for a period of 7.5 years with a further option of 3 years extension upon mutual consent.

Analysis Scores

Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment9/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sai Parenterals Limited has informed the Exchange about Bagging/Receiving of orders/contracts

Attachments (1)

📄

SAIPARENTERALS_01072026164110_Disclosurebaggingoforders.pdf

pdf

Download →
View document text
To, Date: 01st July, 2026 The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Subject: Disclosure under Reg. 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2018. Pursuant to Regulation 30 read with Schedule III, Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we hereby inform the Exchanges that the Company’s subsidiary Noumed Pharmaceuticals Pty Limited had entered OTC medicines Supply Agreement with Australia’s leading pharmacy network with Contract valued at Australian Dollars (AUD) 202 Millions (Equivalent to INR 1300 crores; 1 AUD = INR 64.5). The requisite details in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 are provided below. Name of the entity awarding the Australia’s Leading Pharmacy Network order(s)/contract(s) Significant terms and conditions of Exclusive OTC medicine supply agreement for order(s)/contract(s) awarded in brief a period of 7.5 years with a further option of 3 years extension upon mutual consent Whether order(s) / contract(s) have been International Entity awarded by domestic/ international entity Nature of order(s) / contract(s) Exclusive OTC medicine supply agreement Whether domestic or international International Time period by which the Effective Date: 01 July 2026 order(s)/contract(s) is to be executed Contract Term: 7.5 years with a further option of 3 years extension upon mutual consent broad consideration or size of the At Australian Dollars (AUD) 202 Million order(s)/contract(s) (Equivalent to INR 1300 crores, 1 AUD = INR 64.5). whether the promoter/ promoter group / No, the promoter/ promoter group / group group companies have any interest in the companies do not have any interest in the entity that awarded the order(s)/contract(s)? entity that awarded the order(s)/contract(s) If yes, nature of interest and details thereof whether the order(s)/contract(s) would fall No, the order(s)/contract(s) would not fall within related party transactions? If yes, within related party transactions. whether the same is done at “arm’s length” This is for the information and records of the Exchanges, please. Thanking you, Yours faithfully, For Sai Parenterals Limited Mr. Anil Kumar Karusala Managing Director (DIN- 01866646)